Many Alzheimer’s drug developers close significantly higher thanks to Biogen, Eisai data Posted on September 28, 2022 By Charlielikes Stock Market
Biogen, Eisai Alzheimer’s candidate lecanemab meets primary endpoint in late-stage trial Posted on September 28, 2022 By Charlielikes Stock Market